Artificial antibody polypeptides
AssigneeResearch Corporation Technologies, Inc.
InventorShohei Koide
Life of this patent
Estimating the term…
Abstract
The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.
Claims29
A modified human fibronectin type III (Fn3 ) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to the wild-type human Fn3, wherein the stabilizing mutation is a substitution of at least one of Asp 7, Asp 23 or Glu 9 with a neutral or positively charged amino acid residue, wherein amino acid residue 6 is Arg.
A modified human tenth type III module of fibronectin (FNfn10) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to the wild-type human FNfn10molecule, wherein the stabilizing mutation is a substitution of at least one of amino acid residues 7, 9 or 23 with a neutral or positively charged amino acid residue, wherein amino acid residue 6 is Arg.
A modified human fibronectin type III (Fn3 ) molecule comprising a stabilizing mutation of at least one residue involved in an unfavorable electrostatic interaction as compared to the wild-type human Fn3 , wherein the stabilizing mutation is a substitution of Asp 7 or Asp 23 with a positively charged amino acid residue.
Dependencies are inferred from the claim text.